Skip to search formSkip to main contentSkip to account menu

durvalumab

A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

MEDI4736

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
A 68‐year‐old male patient with squamous cell carcinoma (cT4N2M0) of the left upper lobe received chemoradiotherapy followed by… 
2020
2020
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
226 Background: Based on the positive results of the CALGB 80803 study (J Clin Oncol 2017;35:1 [abstr]), we have added D to… 
Review
2019
Review
2019
Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Identification of targetable mutations such as EGFR has allowed opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung… 
2019
2019
Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM).
8549 Background: Treatment options are limited for patients (pts) with MPM who experience disease progression after first-line… 
Review
2019
Review
2019
Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)
Abstract Background In the Phase III PACIFIC trial of patients with unresectable, Stage III non-small cell lung cancer (NSCLC… 
2018
2018
DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.
8503Background: DREAM is an open-label, single arm, multi-centre, phase II trial with a safety run in designed to determine the… 
2018
2018
Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I…
92Background: Angiogenesis and immunosuppression are hallmarks of tumor growth. This global phase 1 trial evaluates the… 
2017
2017
Exposure-efficacy and safety analysis of durvalumab in patients with urothelial carcinoma (UC) and other solid tumors.
2568Background: Durvalumab is a human monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and CD-80. The… 
2017
2017
Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials.
3038Background: Immunotherapies have improved survival in NSCLC but not all pts benefit. Besides baseline PDL1 expression… 
2016
2016
Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.
4502Background: A Phase 1/2 dose escalation and dose expansion study is evaluating the safety and efficacy of durvalumab, a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)